Financial reports
10-K/A
2013 FY
Annual report (amended)
24 Apr 13
10-K
2012 FY
Annual report
15 Mar 13
10-Q
2012 Q3
Quarterly report
1 Nov 12
10-Q
2012 Q2
Quarterly report
2 Aug 12
10-Q
2012 Q1
Quarterly report
4 May 12
10-K
2011 FY
Annual report
8 Mar 12
10-Q
2011 Q3
Quarterly report
9 Nov 11
10-Q
2011 Q2
Quarterly report
5 Aug 11
10-Q
2011 Q1
Quarterly report
9 May 11
Current reports
8-K
Completion of Acquisition or Disposition of Assets
26 Apr 13
8-K
Obagi Medical Products, Inc. and Valeant Pharmaceuticals, Inc. Agree on an Increased Offer Price of $24.00 per Share in Cash
3 Apr 13
8-K
Entry into a Material Definitive Agreement
20 Mar 13
8-K
Obagi Medical Products Reports Fourth Quarter and Year-End 2012 Financial Results
14 Mar 13
8-K
Other Events
10 Dec 12
8-K
Obagi Medical Products Reports Third Quarter 2012 Earnings; Company Provides Update to Key Initiatives
1 Nov 12
8-K
Entry into a Material Definitive Agreement
29 Oct 12
8-K
Departure of Directors or Certain Officers
16 Aug 12
8-K
Obagi Medical Products’ Reports Second Quarter 2012 EPS Rose to $0.18 vs. $0.16 a Year Ago; Revenue Rose to $30.5 million
2 Aug 12
8-K
Kristina M. Leslie Joins Board of Directors
2 Aug 12
Registration and prospectus
15-12B
Securities registration termination
6 May 13
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Apr 13
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Apr 13
25-NSE
Exchange delisting
25 Apr 13
SC 14D9/A
Tender offer solicitation (amended)
25 Apr 13
SC TO-T/A
Third party tender offer statement (amended)
25 Apr 13
SC 14D9/A
Tender offer solicitation (amended)
24 Apr 13
SC TO-T/A
Third party tender offer statement (amended)
24 Apr 13
SC 14D9/A
Tender offer solicitation (amended)
23 Apr 13
SC TO-T/A
Third party tender offer statement (amended)
23 Apr 13
Proxies
DEFA14A
Additional proxy soliciting materials
10 Dec 12
DFAN14A
Additional proxy materials by non-management
3 Dec 12
DEFA14A
Additional proxy soliciting materials
25 May 12
DEF 14A
Definitive proxy
27 Apr 12
PRE 14A
Preliminary proxy
16 Apr 12
DEF 14A
Definitive proxy
28 Apr 11
DEFA14A
Additional proxy soliciting materials
30 Apr 10
DEFA14A
Additional proxy soliciting materials
8 May 09
DEFR14A
Revised proxy
8 May 09
DEF 14A
Definitive proxy
30 Apr 09
Other
CORRESP
Correspondence with SEC
22 Apr 13
UPLOAD
Letter from SEC
2 Apr 13
UPLOAD
Letter from SEC
2 Apr 13
CT ORDER
Confidential treatment order
4 Oct 12
UPLOAD
Letter from SEC
25 Sep 12
CORRESP
Correspondence with SEC
4 Sep 12
UPLOAD
Letter from SEC
24 Aug 12
CT ORDER
Confidential treatment order
3 Jul 12
CT ORDER
Confidential treatment order
10 Apr 12
CORRESP
Correspondence with SEC
15 Nov 10
Ownership
SC 13D/A
GAMCO INVESTORS, INC. ET AL
13 May 13
SC 13D/A
GAMCO INVESTORS, INC. ET AL
17 Apr 13
SC 13D
GAMCO INVESTORS, INC. ET AL
28 Mar 13
SC 13D/A
DISCOVERY EQUITY PARTNERS, LP
13 Jan 12
SC 13D/A
DISCOVERY EQUITY PARTNERS, LP
22 Dec 11
SC 13D/A
DISCOVERY EQUITY PARTNERS, LP
15 Nov 11
SC 13D/A
DISCOVERY EQUITY PARTNERS, LP
30 Mar 10